Project Grant R37CA301130
Award Date 8/5/25
Completion Date 7/31/30
Dollars Obligated $496K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to Case Western Reserve University to conduct research aimed at understanding the fundamental biological mechanisms of acute myeloid leukemia (AML) and developing new therapeutic approaches. The $491,357 award supports investigations into using proteasome inhibitors and an mTORC1 activator molecule to induce metabolic stress and resensitize AML cells to treatment, particularly...
- This $458,698 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the University of Michigan to identify cellular and molecular mechanisms underlying therapy resistance and disease relapse in acute myeloid leukemia (AML). The project aims to characterize genes and pathways that confer growth advantages to leukemic stem cells, enabling them to persist and regenerate disease after initial clinical remission. This 5-year...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports fundamental research aimed at understanding the biological mechanisms underlying acute myeloid leukemia (AML) development and progression. The $487,973 award to The Leland Stanford Junior University will fund a 5-year project investigating the role of pre-leukemic hematopoietic stem cells (pHSCs) in AML pathogenesis. The research will explore the clonal evolution, kinetics, and cell...
- The National Cancer Institute (NCI) awarded a $1,034,176 Project Grant to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) with an award date of August 18, 2025. The grant aims to understand the mechanisms of aberrant RNA splicing and how it drives the development of various hematological malignancies, including myelodysplastic syndrome, chronic lymphocytic leukemia, and acute myeloid leukemia. The research builds on the institution's past...
- This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $487,542 to the Beckman Research Institute of the City of Hope to conduct research aimed at understanding the role of mitochondrial RNA methylation in acute myeloid leukemia (AML), particularly for high-risk AML subtypes. The key objectives are to determine the functional importance of the mitochondrial methyltransferase METTL17 in AML pathogenesis, dissect...
- This $640,135 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a new generation of potent menin inhibitors that can overcome resistance observed in current menin inhibitor treatments for acute myeloid leukemia (AML) patients. The award recipient, the Regents of the University of Michigan, will leverage its expertise in medicinal chemistry and cancer biology to design and test these next-generation menin...
- This Project Grant award of $502,516 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at Case Western Reserve University focused on developing a small-molecule degrader called SISU-102 to target leukemic stem cells (LSCs) in acute myeloid leukemia (AML). The key objectives are to further investigate the impacts of these HSF1 degraders on LSC self-renewal, identify sensitive and resistant AML subtypes, and explore the underlying mechanisms. This...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the Rector & Visitors of the University of Virginia to conduct research on the role of long noncoding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. This research will provide insights into how noncoding RNAs...
- This $194,688 Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research by Indiana University Indianapolis to investigate the role of the GATA2 gene in acute myeloid leukemia (AML) and the MonoMAC syndrome. The key objectives are to: 1) Define the genes regulated by the normal GATA2 protein and how their expression is altered by AML- and MonoMAC-associated GATA2 mutations, using a novel mouse model and overexpression studies in...
- This $160,500 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of mouse models to investigate the role of Caspase-2 in nucleophosmin (NPM1)-mutated acute myeloid leukemia (AML). The project aims to determine the impact of Caspase-2 loss on the self-renewal and myeloproliferative disease progression of NPM1-mutated AML cells. The research is being conducted by the Baylor College of Medicine, a leading private,...